Patient guide + clinician detail
Dementia is not one disease. It is a syndrome where brain changes become severe enough to interfere with daily life, memory, language, judgment, behavior, movement, attention, or independence.
First principle
Memory loss is only one possible doorway into dementia. Some people first have trouble planning, driving, finding words, judging risk, recognizing visual information, controlling emotions, sleeping normally, or walking steadily.
The cause matters because testing, safety planning, family counseling, medication choices, prognosis, and treatment options can differ by dementia type. Many people have more than one brain process at the same time.
Start with syndrome, tempo, domain pattern, functional impact, medication/toxin burden, delirium screen, mood/sleep contributors, neurologic signs, vascular risk, family history, and collateral history. Then phenotype the likely substrate: AD, DLB/PDD, FTD spectrum, VCID/VaD, alcohol-related cognitive disorder/Wernicke-Korsakoff, prion, NPH, inflammatory, infectious, metabolic, neoplastic, traumatic, or mixed.
Current diagnosis increasingly integrates clinical phenotype with structural imaging, cognitive testing, labs for reversible contributors, and selected biomarkers such as CSF, amyloid/tau PET, and emerging blood tests when appropriate and available.
Types of dementia
Often begins with short-term memory trouble, repeating questions, misplacing items, or getting lost. It is linked with amyloid plaques, tau tangles, synapse loss, and brain shrinkage.
Typical amnestic AD involves entorhinal/hippocampal networks early, but atypical variants include posterior cortical atrophy, logopenic PPA, dysexecutive/frontal AD, and mixed AD-vascular or AD-Lewy phenotypes.
May cause fluctuating alertness, visual hallucinations, REM sleep behavior, Parkinson-like movement, falls, fainting, and sensitivity to some antipsychotic medicines.
Includes dementia with Lewy bodies and Parkinson's disease dementia. Core features include cognitive fluctuations, recurrent visual hallucinations, RBD, and spontaneous parkinsonism; biomarkers may support but do not replace clinical diagnosis.
Often starts younger than typical Alzheimer's. Early changes may involve personality, judgment, empathy, compulsive behavior, eating, speech, or word meaning before memory is the main issue.
FTD spectrum includes bvFTD, semantic and nonfluent/agrammatic PPA, FTD-MND, PSP, and CBS phenotypes, with tau, TDP-43, or FUS pathology and meaningful genetic yield in familial or young-onset cases.
Caused by strokes, small vessel disease, bleeding, or reduced blood flow. Thinking speed, attention, walking, mood, and planning may be affected more than memory at first.
VCID/VaD may follow strategic infarct, multi-infarct disease, lacunar disease, white matter disease, hemorrhage, hypoperfusion, or cerebral amyloid angiopathy. Mixed AD-vascular disease is common.
Long-term heavy alcohol use can injure the brain directly and through poor nutrition. Severe thiamine deficiency can cause Wernicke encephalopathy and Korsakoff syndrome, a major memory disorder.
Assess alcohol neurotoxicity, malnutrition, hepatic encephalopathy, sleep disorders, head trauma, depression, vascular disease, and Wernicke-Korsakoff. Suspected Wernicke encephalopathy is treated urgently with thiamine.
Some problems look like dementia but need different treatment: depression, sleep apnea, medication effects, thyroid disease, vitamin B12 deficiency, normal pressure hydrocephalus, infection, inflammation, tumors, or delirium.
Keep prion disease, autoimmune encephalitis, HIV/syphilis where relevant, NPH, subdural hematoma, tumor, seizures, medication toxicity, OSA, B12/thyroid disease, depression, bipolar disorder, and delirium on the differential when tempo or exam does not fit.
Cause map
Alzheimer's disease is associated with beta-amyloid plaques outside nerve cells and tau tangles inside nerve cells. These changes can disturb communication between brain cells long before severe symptoms appear.
Important: amyloid and tau are part of the story, not the whole story. Inflammation, blood vessels, metabolism, aging biology, and resilience also matter.
AD biology can be conceptualized with amyloid, tau, and neurodegeneration biomarkers, but symptom expression depends on network vulnerability, synaptic loss, reserve, co-pathology, vascular injury, neuroinflammation, and systemic health. Anti-amyloid therapy requires biomarker confirmation and careful risk selection.
Brain cells need constant blood flow. Strokes, mini-strokes, high blood pressure, diabetes, smoking, sleep apnea, atrial fibrillation, cholesterol problems, and small vessel disease can damage the brain over time.
Clue: stepwise decline, walking changes, slowed thinking, or symptoms after a stroke may point to vascular dementia.
Vascular cognitive impairment spans overt infarcts, lacunes, microbleeds, WMH burden, cerebral amyloid angiopathy, hypoperfusion, and endothelial/blood-brain barrier dysfunction. Prevention overlaps with aggressive stroke and cardiovascular risk management.
Some dementias involve proteins that fold or collect abnormally in brain cells. Lewy body dementia is linked with alpha-synuclein. Frontotemporal dementia may involve tau, TDP-43, or other proteins.
Pattern: different proteins tend to affect different networks, so the first symptoms can look very different.
Proteinopathy phenotype can suggest pathology but is imperfect: DLB/PDD with alpha-synuclein, FTD with tau/TDP-43/FUS, PSP/CBD with 4R tau, ALS-FTD with TDP-43/C9orf72, and mixed age-related pathologies such as LATE.
Most dementia is not caused by one gene alone. Some genes, such as APOE, change risk but do not decide a person's future. Rare families have inherited variants that strongly cause early Alzheimer's or frontotemporal dementia.
Family clue: dementia at young ages or across several generations deserves specialist advice before any genetic testing.
APOE epsilon4 is a risk allele, not a deterministic test. Autosomal dominant AD can involve APP, PSEN1, or PSEN2. FTD/ALS spectrum variants include C9orf72, GRN, and MAPT among others. Genetic counseling is essential for predictive testing.
Heavy alcohol exposure can damage the brain and raise risk through falls, sleep disruption, liver disease, poor nutrition, and thiamine deficiency. Some sedatives, anticholinergic medicines, opioids, and mixed medication effects can worsen cognition.
Do not miss: Wernicke encephalopathy can be life-threatening and needs urgent treatment.
Medication review should include anticholinergic burden, benzodiazepines/Z-drugs, opioids, anticonvulsants, dopamine blockers, polypharmacy, OTC sleep aids, and alcohol interactions. Treat suspected Wernicke before glucose when feasible and do not wait for the full triad.
Sleep apnea, depression, hearing loss, loneliness, chronic pain, infections, autoimmune disease, thyroid problems, low B12, kidney or liver failure, and long hospital stays can worsen thinking or mimic dementia.
Hopeful point: some contributors are treatable, even when a degenerative dementia is also present.
Evaluate delirium vulnerability, sleep disorders, depression/anxiety, sensory impairment, metabolic encephalopathy, systemic inflammatory disease, infection risk, seizures, and cognitive reserve. Treatable contributors can change trajectory, safety, and caregiver burden.
Genetics
A family history can raise concern, but many people with a family history never develop dementia, and many people with dementia do not have an obvious family pattern. Testing can affect relatives, insurance planning, emotional wellbeing, and treatment eligibility, so it should usually be discussed with a knowledgeable clinician or genetic counselor.
Genetic evaluation is most useful in early-onset dementia, strong autosomal-dominant pedigrees, FTD/ALS features, atypical syndromes, or when results affect therapy, trial eligibility, or family planning. Pre-test counseling should cover penetrance, variants of uncertain significance, cascade testing, privacy, and psychosocial impact.
Diagnosis
Doctors ask what changed, how fast it changed, what daily tasks are affected, and what family or close contacts have noticed.
Brief office tests and longer neuropsychology testing can show which thinking systems are affected.
Tests may look for thyroid disease, vitamin B12 deficiency, anemia, infection clues, kidney or liver problems, diabetes, and medication effects.
MRI or CT can look for stroke, bleeding, tumor, hydrocephalus, shrinkage patterns, or other structural causes.
Depression, anxiety, poor sleep, sleep apnea, pain, and hearing or vision loss can strongly affect thinking.
In selected people, PET scans, spinal fluid, or blood biomarker tests may help identify Alzheimer's-related changes.
Driving, falls, cooking, medicines, finances, wandering risk, and caregiver strain should be discussed early.
Diagnosis may take more than one visit, because patterns become clearer when symptoms and tests are followed over time.
Separate delirium, subacute, rapidly progressive, stepwise, and slowly progressive syndromes. Obtain informant history and functional staging.
Amnestic, dysexecutive, visuospatial, language, behavioral, motor, sleep/autonomic, psychiatric, and focal neurologic patterns narrow the differential.
CBC, CMP, TSH, B12, depression screen, medication review; add HIV, syphilis, inflammatory, autoimmune, toxic, or metabolic tests when risk or tempo supports it.
MRI preferred when available: infarcts, WMH, microbleeds, CAA pattern, medial temporal atrophy, frontal/temporal asymmetry, NPH, mass, subdural.
Useful for mild/atypical cases, occupational decisions, longitudinal measurement, capacity questions, and differentiating mood/sleep from neurodegeneration.
CSF A-beta/tau, amyloid PET, tau PET, and validated blood biomarkers can support AD diagnosis, treatment selection, or trial referral in the right clinical context.
EEG, LP, autoimmune/prion workup, sleep study, DAT imaging, FDG-PET, genetic counseling, or movement-disorders evaluation may be appropriate.
Stage severity, disclose clearly, address advance care planning, driving, medications, caregiver needs, neuropsychiatric symptoms, and community supports.
Prevention and prognosis
Heart and blood vessel health are brain health. Treat high blood pressure, diabetes, atrial fibrillation, sleep apnea, and stroke risk.
Regular activity, enough sleep, hearing correction, social connection, and mental engagement may help maintain function and independence.
Avoid tobacco, limit alcohol, prevent head injuries, and review medicines that can worsen thinking or balance.
Alzheimer's, Lewy body, FTD, vascular, and alcohol-related dementia can progress differently. Early diagnosis gives time for treatment choices and support planning.
Images and tests
Sources